Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/3/2026

1. PANW
2. GTLB
3. DELL
4. MDB
5. GOOGL

6. VRTS
7. SPY
8. HPE
9. USO
10. SNOW

Get Alerts RYTM Hot Sheet

Price: $105.42 +0.65%

Overall Analyst Rating:
SELL (= Flat)

Revenue Growth %: +63.6%

Join SI Premium – FREE

BOSTON, March 07, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that company management will present a corporate update at two investor conferences in March:

Cowen and Company 38th Annual Health Care ConferenceDate: Wednesday, March 14, 2018Time: 10:40 a.m. ETLocation: Boston, MA

17th Annual Needham Healthcare ConferenceDate: Wednesday, March 28, 2018Time: 1:30 p.m. ETLocation: New York, NY

Live audio webcasts of both presentations will be available under “Events & Presentations” in the Investors & Media section of the Company’s website at www.rhythmtx.com. Replays of the webcasts will be available on the Rhythm website for 30 days following each presentation.

About RhythmRhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. Rhythm’s lead product candidate is setmelanotide, a first-in-class melanocortin-4 receptor (MC4R) agonist. Rhythm also supports The Genetic Obesity Project (www.GeneticObesity.com), which is dedicated to improving the understanding of severe obesity that results from specific genetic disorders. The company is based in Boston, MA.

Investor Contact:Hannah DeresiewiczStern Investor Relations, Inc.212-362-1200[email protected]

Media Contact:Adam Daley Berry & Company Public Relations212-253-8881[email protected]